|
AU4777896A
(en)
*
|
1995-02-10 |
1996-08-27 |
G.D. Searle & Co. |
Use of low dose amount of spironolactone for treatment of cardiovascular disease
|
|
AR030414A1
(es)
*
|
2000-04-03 |
2003-08-20 |
Astrazeneca Ab |
Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
|
|
SE0002354D0
(sv)
*
|
2000-06-22 |
2000-06-22 |
Astrazeneca Ab |
New formulation
|
|
FI20010233A0
(fi)
*
|
2001-02-08 |
2001-02-08 |
Orion Corp |
Menetelmä sydämen vajaatoiminnan hoitoon
|
|
FI20011464A0
(fi)
*
|
2001-07-04 |
2001-07-04 |
Orion Corp |
Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
|
|
US7020521B1
(en)
|
2002-11-08 |
2006-03-28 |
Pacesetter, Inc. |
Methods and apparatus for detecting and/or monitoring heart failure
|
|
WO2005049022A2
(en)
|
2003-11-17 |
2005-06-02 |
Novartis Ag |
Use of dipeptidyl peptidase iv inhibitors
|
|
EP1699436A2
(en)
*
|
2003-12-12 |
2006-09-13 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
|
|
JP2007530566A
(ja)
*
|
2004-03-22 |
2007-11-01 |
ミオゲン インコーポレイティッド |
（ｒ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
|
|
CA2560528A1
(en)
*
|
2004-03-22 |
2005-10-06 |
Myogen, Inc. |
(s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
EP1776108A1
(en)
*
|
2004-06-23 |
2007-04-25 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of pde-iii mediated diseases
|
|
CA2581086C
(en)
|
2004-09-14 |
2023-11-07 |
The Regents Of The University Of Colorado, A Body Corporate |
Method for treatment with bucindolol based on genetic targeting
|
|
US20090317376A1
(en)
|
2005-06-06 |
2009-12-24 |
Georgetown University Medical School |
Compositions And Methods For Lipo Modeling
|
|
WO2007014029A2
(en)
*
|
2005-07-22 |
2007-02-01 |
The Regents Of The University Of Colorado, A Body Corporate |
Yin yang 1 as a treatment for cardiac hypertrophy and heart failure
|
|
US9512481B2
(en)
|
2009-09-11 |
2016-12-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Polymorphisms in the PDE3A gene
|
|
WO2018128999A1
(en)
*
|
2017-01-03 |
2018-07-12 |
Cardioxyl Pharmaceuticals, Inc. |
Method of administering nitroxyl donating compounds
|
|
IL283725B2
(en)
|
2017-06-20 |
2024-04-01 |
Imbria Pharmaceuticals Inc |
Compositions and methods for increasing efficiency of cardiac metabolism
|
|
EP3866794B1
(en)
|
2018-10-17 |
2024-12-04 |
Imbria Pharmaceuticals, Inc. |
Methods of treating rheumatic diseases using trimetazidine-based compounds
|
|
EP3976101A4
(en)
|
2019-05-31 |
2023-06-21 |
Imbria Pharmaceuticals, Inc. |
FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
|
|
EP4146215A4
(en)
*
|
2020-05-04 |
2024-05-01 |
Imbria Pharmaceuticals, Inc. |
DOSAGE METHODS FOR TREATMENT OF CARDIOVASCULAR PROBLEMS
|
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|